WUHAN -- Am I obese or not? This is a question asked worldwide, and body mass index (BMI) has long been the core indicator for determining obesity. A new study by Chinese and international scientists, however, has validated a refined diagnostic framework that moves beyond the conventional BMI-based classification.
The study systematically validated the refined diagnostic framework proposed by the Lancet Commission, indicating that the global obesity diagnosis and treatment system needs to enter a new stage centered on precise assessment and healthy function, according to Huazhong University of Science and Technology (HUST) in Central China.
Published in the journal Nature, the study was carried out by researchers at the School of Public Health of Tongji Medical College of HUST, in collaboration with global researchers at multiple institutions.
Previous studies indicated that obesity significantly increases risks of cardiometabolic diseases and many organ dysfunctions. In both clinical practice and daily life, BMI is widely used as the core indicator for screening and determining obesity.
"Notably, BMI can help calculate the relationship between weight and height. However, as a diagnostic criterion, it has inherent limitations, and it cannot distinguish whether the added mass is muscle or fat. It also cannot determine whether accumulated fat has already damaged internal organs. Diagnosis based solely on BMI can easily lead to missed diagnoses and misdiagnosis," said Pan An, a HUST professor and the study leader.
The joint team conducted a comparative performance study of the Lancet Commission's clinical obesity diagnostic framework against conventional BMI-based classification, using prevalence, incidence and mortality data from over 840,000 adults across four cohorts in China, Britain, the United States and Spain.
The study showed that BMI underestimated the degree of obesity in 5.2 percent to 8.6 percent of participants and overestimated it in 1.2 percent to 3.1 percent of participants across the four cohorts.
It also indicated that although many people have substantial fat accumulation, they do not show organ function impairment attributable to obesity. Therefore, it is necessary to distinguish between clinical obesity and preclinical obesity.
Long-term follow-up visits also indicated that preclinical obesity does not necessarily mean a rapid development into clinical obesity.
In three of the study's cohorts, followed for more than 10 years, about 77 percent to 91 percent of people with preclinical obesity did not progress to clinical obesity.
Regarding long-term mortality risk, compared with those who had neither obesity nor organ function impairment, the all-cause mortality risk of people with preclinical obesity increased by 19 percent, while that of people with clinical obesity rose by 69 percent.
This indicates that as long as timely scientific interventions and lifestyle modifications are carried out in the early-to-middle stages when organs are not yet damaged, such measures can help delay worsening of the condition and safeguard the bottom line of health, the study noted.
"Our new study confirms that the diagnosis of obesity should not stop at body weight, but should further focus on a person's actual health status. It breaks the conventional, broad-brush concept of weight loss and helps guide the public health system to transform from mere weight control to maintaining organ health," Pan said.
According to Pan, it is also important to upgrade and reshape the clinical diagnosis and treatment system, and to advance global health policy.
"The public should also ease anxiety, undergo precise assessments and pay attention to their organ function status — this is the key to addressing obesity and safeguarding health in a more scientific manner," he added.
